[
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Announces Positive Results For Hemophilia Treatment And Declares $0.43 Dividend",
    "summary": "Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third-quarter 2025 dividend of $0.43 per share. Alongside these developments, the company reported various clinical trial updates and strategic agreements. Over the last month, Pfizer's share price rose by 4%, slightly outperforming the broader market's 1.7% increase in the past week. These advances, along with sustained dividend distribution, likely reinforced investor...",
    "url": "https://finnhub.io/api/news?id=d3d09d9861789a5861c6fee22f2461f9300fd0bc10a2dd383cac474a65ddf38b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750959305,
      "headline": "Pfizer (NYSE:PFE) Announces Positive Results For Hemophilia Treatment And Declares $0.43 Dividend",
      "id": 135576194,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third-quarter 2025 dividend of $0.43 per share. Alongside these developments, the company reported various clinical trial updates and strategic agreements. Over the last month, Pfizer's share price rose by 4%, slightly outperforming the broader market's 1.7% increase in the past week. These advances, along with sustained dividend distribution, likely reinforced investor...",
      "url": "https://finnhub.io/api/news?id=d3d09d9861789a5861c6fee22f2461f9300fd0bc10a2dd383cac474a65ddf38b"
    }
  },
  {
    "ts": null,
    "headline": "All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy",
    "summary": "Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
    "url": "https://finnhub.io/api/news?id=f1ec5495189d964964ee62b2ce7b5fc5381ec8ecba7081f858fa0b2429f521cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750953603,
      "headline": "All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy",
      "id": 135576195,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
      "url": "https://finnhub.io/api/news?id=f1ec5495189d964964ee62b2ce7b5fc5381ec8ecba7081f858fa0b2429f521cf"
    }
  },
  {
    "ts": null,
    "headline": "Smartly’s Flagship Event ADVANCE Returns: New Voices, Big Ideas, and the Future of Marketing",
    "summary": "NEW YORK, June 26, 2025--ADVANCE, the flagship event from Smartly, the leading AI-powered advertising technology platform, returns to New York City on September 17.",
    "url": "https://finnhub.io/api/news?id=18d5f0080b3f9ee6650510d3c454f4c7de3fa1229608749d831717fabcc83639",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750944600,
      "headline": "Smartly’s Flagship Event ADVANCE Returns: New Voices, Big Ideas, and the Future of Marketing",
      "id": 135558429,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, June 26, 2025--ADVANCE, the flagship event from Smartly, the leading AI-powered advertising technology platform, returns to New York City on September 17.",
      "url": "https://finnhub.io/api/news?id=18d5f0080b3f9ee6650510d3c454f4c7de3fa1229608749d831717fabcc83639"
    }
  },
  {
    "ts": null,
    "headline": "Innovation in Focus: Highlights from the Two-Day London Biotechnology Show 2025",
    "summary": "The London Biotechnology Show 2025, held from 18 to 19 June, encompassed a range of sessions on automation, regulation, and innovation, amongst others.",
    "url": "https://finnhub.io/api/news?id=f19e281f961e7d26e16b926ea962ea051231336e163e2ffeba28cffc384c5867",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750939543,
      "headline": "Innovation in Focus: Highlights from the Two-Day London Biotechnology Show 2025",
      "id": 135557276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The London Biotechnology Show 2025, held from 18 to 19 June, encompassed a range of sessions on automation, regulation, and innovation, amongst others.",
      "url": "https://finnhub.io/api/news?id=f19e281f961e7d26e16b926ea962ea051231336e163e2ffeba28cffc384c5867"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors",
    "summary": "NEW YORK, June 26, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HYMPAVZI in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatm",
    "url": "https://finnhub.io/api/news?id=ca0042557fb0e16efb7eb149896709f755cc589c8f3dd77a26ced8deee689fea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750934700,
      "headline": "Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors",
      "id": 135553599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, June 26, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HYMPAVZI in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatm",
      "url": "https://finnhub.io/api/news?id=ca0042557fb0e16efb7eb149896709f755cc589c8f3dd77a26ced8deee689fea"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: positive phase 3 results in hemophilia",
    "summary": "Pfizer reported positive results on Thursday from a Phase 3 study of Hympavzi, its experimental treatment for hemophilia A or B with inhibitors.The US pharmaceutical company said the trial met its...",
    "url": "https://finnhub.io/api/news?id=11bed89a47ac58660575d64ea13fe832d94835fdb7527890dfd559701628255c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750926328,
      "headline": "Pfizer: positive phase 3 results in hemophilia",
      "id": 135556575,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer reported positive results on Thursday from a Phase 3 study of Hympavzi, its experimental treatment for hemophilia A or B with inhibitors.The US pharmaceutical company said the trial met its...",
      "url": "https://finnhub.io/api/news?id=11bed89a47ac58660575d64ea13fe832d94835fdb7527890dfd559701628255c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. Announces Positive Topline Phase 3 Results for Hympavzi?? in Hemophilia A or B with Inhibitors",
    "summary": "Pfizer Inc. announced positive topline results from the Phase 3 BASIS study evaluating HYMPAVZI?? for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary...",
    "url": "https://finnhub.io/api/news?id=330f01940b6630bd30fc5b7ff74225af29de4db1d1a1ff729a7a0a4f4a7fb67c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750924233,
      "headline": "Pfizer Inc. Announces Positive Topline Phase 3 Results for Hympavzi?? in Hemophilia A or B with Inhibitors",
      "id": 135555193,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Inc. announced positive topline results from the Phase 3 BASIS study evaluating HYMPAVZI?? for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary...",
      "url": "https://finnhub.io/api/news?id=330f01940b6630bd30fc5b7ff74225af29de4db1d1a1ff729a7a0a4f4a7fb67c"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Hympavzi Hits Key Goals in Hemophilia With Inhibitors",
    "summary": "By Colin Kellaher Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments...",
    "url": "https://finnhub.io/api/news?id=d3bfa2ff160d4412e565e52c87131dcad729acc84edd7295b3850355822736e0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750923132,
      "headline": "Pfizer's Hympavzi Hits Key Goals in Hemophilia With Inhibitors",
      "id": 135554271,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments...",
      "url": "https://finnhub.io/api/news?id=d3bfa2ff160d4412e565e52c87131dcad729acc84edd7295b3850355822736e0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies",
    "summary": "Pfizer's hemophilia therapy,Hympavzi, met the main goal of a late-stage study in patientswith certain types of antibodies, the U.S. drugmaker said onThursday. The data comes months...",
    "url": "https://finnhub.io/api/news?id=96f2ea4544c42d806db4b9fc5f2ad370361d938c53370defaaec2f7d9aad8d24",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750921831,
      "headline": "Pfizer's bleeding disorder therapy succeeds in trial with patients with certain antibodies",
      "id": 135554824,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer's hemophilia therapy,Hympavzi, met the main goal of a late-stage study in patientswith certain types of antibodies, the U.S. drugmaker said onThursday. The data comes months...",
      "url": "https://finnhub.io/api/news?id=96f2ea4544c42d806db4b9fc5f2ad370361d938c53370defaaec2f7d9aad8d24"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's bleeding disorder therapy meets main goal in patients with certain antibodies",
    "summary": "Pfizer said on Thursday itshemophilia therapy, Hympavzi, met the main goal of a late-stagestudy in patients with certain types of antibodies. The data comes months after Pfizer said it...",
    "url": "https://finnhub.io/api/news?id=a4a7b6d4808d482b4e4d61d0b924820b9f5922e6bb36a873ae46077dcd73167e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750921831,
      "headline": "Pfizer's bleeding disorder therapy meets main goal in patients with certain antibodies",
      "id": 135552774,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer said on Thursday itshemophilia therapy, Hympavzi, met the main goal of a late-stagestudy in patients with certain types of antibodies. The data comes months after Pfizer said it...",
      "url": "https://finnhub.io/api/news?id=a4a7b6d4808d482b4e4d61d0b924820b9f5922e6bb36a873ae46077dcd73167e"
    }
  }
]